Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
暂无分享,去创建一个
Yihan Yao | Yali Wang | Anwen Shao | Jianmin Zhang | Yongchuan Deng | Lihong Liu | Yunxiang Zhou | Shijie Wu | Yanyan Xu | Qiang Chen
[1] B. Baradaran,et al. Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. , 2020, European journal of pharmacology.
[2] Xudong Huang,et al. The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway , 2020, Nanoscale Research Letters.
[3] Li Hai,et al. Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer. , 2020, European journal of medicinal chemistry.
[4] Glycolysis Inhibition , 2020, Definitions.
[5] Huan Tang,et al. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity , 2020, International journal of nanomedicine.
[6] Jian-hai Chen,et al. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis , 2020, Journal of Nanobiotechnology.
[7] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[8] 石川 聡,et al. Matrix Metalloproteinase , 1997, Definitions.
[9] Lijuan Wen,et al. Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer , 2019, International journal of nanomedicine.
[10] M. Xie,et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment , 2019, Molecular Cancer.
[11] Jin-yuan He,et al. Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy , 2019, Nanoscale Research Letters.
[12] X. Gu,et al. Ceramide–Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations , 2019, Molecular Cancer Therapeutics.
[13] Yuanyuan Liu,et al. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer , 2019, Journal of Nanobiotechnology.
[14] Man Li,et al. Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle. , 2019, ACS applied materials & interfaces.
[15] Umile Gianfranco Spizzirri,et al. Combining Carbon Nanotubes and Chitosan for the Vectorization of Methotrexate to Lung Cancer Cells , 2019, Materials.
[16] Qinfu Zhao,et al. Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy. , 2019, Materials science & engineering. C, Materials for biological applications.
[17] F. Gao,et al. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment , 2019, Theranostics.
[18] A. Rawlings,et al. Targeted magnetic nanoparticle hyperthermia for the treatment of oral cancer. , 2019, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[19] J. Zink,et al. Supramolecular Nanomachines as Stimuli-Responsive Gatekeepers on Mesoporous Silica Nanoparticles for Antibiotic and Cancer Drug Delivery , 2019, Theranostics.
[20] Chengzhong Yu,et al. Mesoporous Silica Nanoparticles for Protein Protection and Delivery , 2019, Front. Chem..
[21] D. Mondhe,et al. Gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for improved efficacy of cancer chemotherapy. , 2019, Materials science & engineering. C, Materials for biological applications.
[22] Dnyaneshwar Kalyane,et al. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. , 2019, Materials science & engineering. C, Materials for biological applications.
[23] P. Hammond,et al. Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo Using Layer‐by‐Layer Nanoparticles , 2019, Advanced functional materials.
[24] J. Das,et al. pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy , 2019, Journal of advanced research.
[25] N. Ferrara,et al. VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.
[26] V. Awasthi,et al. Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer , 2019, Materials.
[27] Mingxiong Sheng,et al. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment. , 2019, Colloids and surfaces. B, Biointerfaces.
[28] M. Farokhi,et al. New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[29] S. Ku,et al. Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells , 2019, Pharmaceutics.
[30] Wuli Yang,et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. , 2019, Biomaterials.
[31] F. Fanizzi,et al. Design and Application of Cisplatin-Loaded Magnetic Nanoparticle Clusters for Smart Chemotherapy. , 2019, ACS applied materials & interfaces.
[32] Yiguo Jiang,et al. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. , 2019, Biomaterials.
[33] Xinru You,et al. Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives. , 2019, Current topics in medicinal chemistry.
[34] K. Greish,et al. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity , 2018, International journal of nanomedicine.
[35] Wei He,et al. A drug-delivering-drug strategy for combined treatment of metastatic breast cancer. , 2018, Nanomedicine : nanotechnology, biology, and medicine.
[36] Hao Hu,et al. A degradable triple temperature-, pH-, and redox-responsive drug system for cancer chemotherapy. , 2018, Journal of biomedical materials research. Part A.
[37] A. Sherje,et al. Dendrimers: A versatile nanocarrier for drug delivery and targeting , 2018, International journal of pharmaceutics.
[38] J. Leung. Recent Advances in Nanoparticle-Based Cancer Drug Delivery , 2018 .
[39] Ankita Dadwal,et al. Nanoparticles as carriers for drug delivery in cancer , 2018, Artificial cells, nanomedicine, and biotechnology.
[40] J. Lillard,et al. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. , 2018, Cancer letters.
[41] Kwangmeyung Kim,et al. Engineering nanoparticle strategies for effective cancer immunotherapy. , 2018, Biomaterials.
[42] Ronnie H. Fang,et al. Cell Membrane Coating Nanotechnology , 2018, Advanced materials.
[43] Q. Lu,et al. A Tumor Vascular‐Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia , 2018, Advanced science.
[44] Haifeng Dong,et al. Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma. , 2018, ACS nano.
[45] Hong Wu,et al. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy , 2018, International journal of nanomedicine.
[46] Xiaoqi Sun,et al. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. , 2018, ACS nano.
[47] Qi Zhang,et al. Hypoxia‐inducible factor‐1α/interleukin‐1β signaling enhances hepatoma epithelial–mesenchymal transition through macrophages in a hypoxic‐inflammatory microenvironment , 2018, Hepatology.
[48] J. Fisher,et al. Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial , 2018, ACS central science.
[49] K. Lam,et al. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. , 2018, Nanomedicine : nanotechnology, biology, and medicine.
[50] F. Akbaş,et al. Magnetic nanoparticle-mediated gene therapy to induce Fas apoptosis pathway in breast cancer , 2018, Cancer Gene Therapy.
[51] Wei Li,et al. Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy , 2018, Advanced materials.
[52] C. Jaroniec,et al. Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance , 2018, Nature Communications.
[53] Hongwei Cheng,et al. Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. , 2018, Materials science & engineering. C, Materials for biological applications.
[54] S. Sigismund,et al. Emerging functions of the EGFR in cancer , 2017, Molecular oncology.
[55] Robert J. Lee,et al. Recent Advances and Perspectives in Liposomes for Cutaneous Drug Delivery. , 2017, Current medicinal chemistry.
[56] Lei Wu,et al. Multifunctional micelle delivery system for overcoming multidrug resistance of doxorubicin , 2017, Journal of drug targeting.
[57] F. Rizzolio,et al. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes. , 2017, Current medicinal chemistry.
[58] Sang J. Chung,et al. Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy. , 2016, Current drug targets.
[59] R. Ramesh,et al. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. , 2018, Advances in cancer research.
[60] Hairong Zheng,et al. Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome. , 2017, Biomaterials.
[61] M. Yousefi,et al. Nanoparticles and targeted drug delivery in cancer therapy. , 2017, Immunology letters.
[62] H. Santos,et al. Nutlin‐3a and Cytokine Co‐loaded Spermine‐Modified Acetalated Dextran Nanoparticles for Cancer Chemo‐Immunotherapy , 2017 .
[63] Zhigui Su,et al. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. , 2017, International journal of pharmaceutics.
[64] C. Cooper,et al. Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer , 2017, Scientific Reports.
[65] Rachel S. Riley,et al. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[66] R. Kerbel,et al. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. , 2017, Trends in cancer.
[67] Yihui Deng,et al. Nanoparticles for tumor immunotherapy , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[68] Peng Li,et al. iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability , 2017, International journal of nanomedicine.
[69] Qinghua Xu,et al. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin , 2017, Acta Pharmacologica Sinica.
[70] P. V. Bramhachari,et al. Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer. , 2017, Critical reviews in oncology/hematology.
[71] Ronnie H. Fang,et al. Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization , 2017, Advanced materials.
[72] D. Chiappetta,et al. Polymeric mixed micelles as nanomedicines: Achievements and perspectives. , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[73] F. Zhang,et al. Receptor-Mediated Surface Charge Inversion Platform Based on Porous Silicon Nanoparticles for Efficient Cancer Cell Recognition and Combination Therapy. , 2017, ACS applied materials & interfaces.
[74] Nicole F. Steinmetz,et al. Hypo-fractionated radiation, magnetic nanoparticle hyperthermia and a viral immunotherapy treatment of spontaneous canine cancer , 2017, BiOS.
[75] S. Rocchiccioli,et al. Rational Design of a Transferrin-Binding Peptide Sequence Tailored to Targeted Nanoparticle Internalization. , 2017, Bioconjugate chemistry.
[76] Jarno Salonen,et al. Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy , 2017, Advanced materials.
[77] R. Zhang,et al. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. , 2017, Nanoscale.
[78] Tumor‐targeted micelle‐forming block copolymers for overcoming of multidrug resistance , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[79] Hélder A Santos,et al. Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy? , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[80] Q. Mei,et al. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance , 2016, Scientific Reports.
[81] B. Baradaran,et al. Overview on experimental models of interactions between nanoparticles and the immune system. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[82] Y. Assaraf,et al. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[83] R. Ramesh,et al. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration , 2016, Journal of Nanobiotechnology.
[84] H. Samadian,et al. Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy , 2016, Journal of Cancer Research and Clinical Oncology.
[85] Sandro Matosevic,et al. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape , 2016, Drug delivery.
[86] J. M. Marchetti,et al. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. , 2016, Colloids and surfaces. B, Biointerfaces.
[87] Chen Wang,et al. Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo , 2016, Scientific Reports.
[88] V. Rotello,et al. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems , 2016, Expert opinion on drug delivery.
[89] K. Alitalo,et al. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy , 2016, Journal of drug targeting.
[90] M. Ehrich,et al. Engineering the lipid layer of lipid-PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability. , 2015, Acta biomaterialia.
[91] R. Ramesh,et al. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy , 2015, International journal of nanomedicine.
[92] M. Papi,et al. Killing cancer cells using nanotechnology: novel poly(I:C) loaded liposome-silica hybrid nanoparticles. , 2015, Journal of materials chemistry. B.
[93] Da Xing,et al. Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy. , 2015, Biomaterials.
[94] J. Ong,et al. Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy. , 2015, Biomaterials.
[95] Dong Wang,et al. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma. , 2015, ACS nano.
[96] Jarno Salonen,et al. Inhibition of Multidrug Resistance of Cancer Cells by Co‐Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes , 2015 .
[97] J. Chen,et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. , 2015, Biomaterials.
[98] D. A. Russell,et al. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles , 2015, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[99] Meiying Wang,et al. Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice , 2015, ACS nano.
[100] Yang Yang,et al. Nanoparticle-based immunotherapy for cancer. , 2015, ACS nano.
[101] C. Sykes,et al. Cell-sized liposomes that mimic cell motility and the cell cortex. , 2015, Methods in cell biology.
[102] Leaf Huang,et al. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. , 2015, Advanced drug delivery reviews.
[103] Yiye Li,et al. Co-delivery of HIF 1 a siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer , 2015 .
[104] Patrick V. Almeida,et al. Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. , 2014, Nanoscale.
[105] Gang Zheng,et al. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. , 2014, ACS nano.
[106] S. Lai,et al. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. , 2014, Molecular pharmaceutics.
[107] Xiaoyang Xu,et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.
[108] Yasuhiko Yoshida,et al. Curcumin and 5-Fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia , 2014, International journal of nanomedicine.
[109] M. Edidin,et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[110] S. Wu,et al. The use of lipid-based nanocarriers for targeted pain therapies , 2013, Front. Pharmacol..
[111] E. Luo,et al. The toxicity and pharmacokinetics of carbon nanotubes as an effective drug carrier. , 2013, Current drug metabolism.
[112] Q. Lu,et al. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer. , 2013, Biomaterials.
[113] S. Cheng,et al. Surface functionalized gold nanoparticles for drug delivery. , 2013, Journal of biomedical nanotechnology.
[114] Mohammad Wahid Ansari,et al. The legal status of in vitro embryos , 2014 .
[115] C. Figdor,et al. Dendritic cell-based nanovaccines for cancer immunotherapy. , 2013, Current opinion in immunology.
[116] Lili Li,et al. Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics. , 2013, Molecular pharmaceutics.
[117] E. Skaret. The Combined Treatment , 2013 .
[118] R. Schreiber,et al. Programmable nanoparticle functionalization for in vivo targeting , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[119] Anne L. van de Ven,et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.
[120] R. Burgess. Nanoparticle-Based Drug Delivery , 2012 .
[121] Y. Maitani,et al. Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. , 2012, Biological & pharmaceutical bulletin.
[122] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[123] Omid C Farokhzad,et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. , 2012, Chemical Society reviews.
[124] V. Torchilin,et al. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. , 2012, Nanomedicine.
[125] N. Jing,et al. Combined treatment targeting HIF‐1α and Stat3 is a potent strategy for prostate cancer therapy , 2011, The Prostate.
[126] A. Seifalian,et al. A new era of cancer treatment: carbon nanotubes as drug delivery tools , 2011, International journal of nanomedicine.
[127] Wean Sin Cheow,et al. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. , 2011, Colloids and surfaces. B, Biointerfaces.
[128] Omid C Farokhzad,et al. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. , 2011, Accounts of chemical research.
[129] Xuan Liu,et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. , 2011, Carcinogenesis.
[130] S. Sahoo,et al. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. , 2011, Molecular pharmaceutics.
[131] S. Sahoo,et al. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.
[132] Dai Fukumura,et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.
[133] Yu Matsumoto,et al. Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting , 2011, Science Translational Medicine.
[134] Véronique Préat,et al. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[135] S. Sahoo,et al. Cancer nanotechnology: application of nanotechnology in cancer therapy. , 2010, Drug discovery today.
[136] D. Sawyer,et al. Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage , 2010, Current hypertension reports.
[137] B. Liu,et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[138] Qian Yang,et al. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. , 2010, Biomaterials.
[139] S. Esener,et al. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. , 2010, Molecular pharmaceutics.
[140] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[141] Z. Duan,et al. Augmentation of Therapeutic Efficacy in Drug-Resistant Tumor Models Using Ceramide Coadministration in Temporal-Controlled Polymer-Blend Nanoparticle Delivery Systems , 2010, The AAPS Journal.
[142] Cristina Saura,et al. Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer , 2010 .
[143] Jayanth Panyam,et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.
[144] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[145] Min Zhang,et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.
[146] Arun K Iyer,et al. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma , 2009, BMC Cancer.
[147] B. Nanjwade,et al. Dendrimers: emerging polymers for drug-delivery systems. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[148] Jin-Ao Duan,et al. Selective matrix metalloproteinase inhibitors for cancer. , 2009, Current medicinal chemistry.
[149] Kyung-Hwa Yoo,et al. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. , 2009, ACS nano.
[150] P. Low,et al. Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.
[151] Warren C W Chan,et al. Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.
[152] Robert Langer,et al. Impact of nanotechnology on drug delivery. , 2009, ACS nano.
[153] Pamela Basto,et al. HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy , 2008, ChemMedChem.
[154] T. Minko,et al. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. , 2008, Nanomedicine.
[155] Robert Langer,et al. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.
[156] W. Ahn,et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[157] Y. Shiying,et al. Effects of hypoxia on expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line , 2005, Journal of Huazhong University of Science and Technology [Medical Sciences].
[158] Mauro Ferrari,et al. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.
[159] L. Zitvogel,et al. Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.
[160] Z. Duan,et al. Paclitaxel and ceramide co‐administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer , 2007, International journal of cancer.
[161] G. Semenza. Evaluation of HIF-1 inhibitors as anticancer agents. , 2007, Drug discovery today.
[162] Vincent M Rotello,et al. Functionalized gold nanoparticles for drug delivery. , 2007, Nanomedicine.
[163] Ho Sup Yoon,et al. Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.
[164] H. Pelicano,et al. Glycolysis inhibition for anticancer treatment , 2006, Oncogene.
[165] Chintamani,et al. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study , 2005, World journal of surgical oncology.
[166] J. Fries,et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. , 2005, Journal of the National Cancer Institute.
[167] Bengt Rippe,et al. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. , 2005, American journal of physiology. Renal physiology.
[168] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[169] Shiying Yu,et al. Effects of hypoxia on expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line. , 2005, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.
[170] B. Zhivotovsky,et al. Apoptotic pathways and therapy resistance in human malignancies. , 2005, Advances in cancer research.
[171] J E Kipp,et al. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. , 2004, International journal of pharmaceutics.
[172] V. Labhasetwar,et al. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. , 2004, Molecular pharmaceutics.
[173] T. Minko. Drug targeting to the colon with lectins and neoglycoconjugates. , 2004, Advanced drug delivery reviews.
[174] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[175] Michael S. Pepper,et al. αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro , 2004, Angiogenesis.
[176] I. Fichtner,et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. , 2003, Cancer research.
[177] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[178] S. Goodman,et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. , 2003, Angiogenesis.
[179] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[180] E. Ruoslahti. Specialization of tumour vasculature , 2002, Nature Reviews Cancer.
[181] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[182] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[183] J. Wijnholds,et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. , 2000, Cancer research.
[184] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[185] E. Hudson,et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.
[186] P Couvreur,et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.
[187] E. Schneider,et al. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. , 1998, FEMS microbiology reviews.
[188] R K Jain,et al. Barriers to drug delivery in solid tumors. , 1994, Scientific American.
[189] P. Couvreur,et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. , 1992, Biochemical pharmacology.
[190] J. Obrecht. [Cancer therapy]. , 1977, Deutsche medizinische Wochenschrift.